Group 1 - The core point of the news is that Shuyou Shen's stock price has increased by 5.65% on February 6, reaching 29.00 CNY per share, with a total market capitalization of 13.855 billion CNY and a trading volume of 437 million CNY, marking a cumulative increase of 10.2% over three consecutive days [1] - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shuyou Shen includes 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - According to data, CITIC Prudential Fund has a significant holding in Shuyou Shen, with the CITIC Prudential Zhi Rui Mixed A Fund (003432) increasing its holdings by 60,000 shares in the fourth quarter, totaling 355,000 shares, which represents 4% of the fund's net value [2] - The fund has generated a floating profit of approximately 550,300 CNY today and a total of 901,700 CNY during the three-day increase [2] - The CITIC Prudential Zhi Rui Mixed A Fund was established on October 21, 2016, with a current size of 134 million CNY, and has achieved a year-to-date return of 0.45% [2]

Core Viewpoint - On January 30, Shutaishen's stock increased by 0.63% with a trading volume of 395 million yuan, indicating a positive market response to the company's recent performance and activities [1]. Financing Summary - On January 30, Shutaishen had a financing buy-in amount of 20.81 million yuan, with a current financing balance of 133 million yuan, accounting for 1.08% of the circulating market value [2]. - The company had no short selling activity on January 30, with both short selling repayment and selling amounting to 0.00 shares and 0.00 yuan respectively [2]. Company Overview - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [2]. - The main revenue sources for Shutaishen include: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [2]. Financial Performance - For the period from January to September 2025, Shutaishen reported an operating income of 181 million yuan, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million yuan, a year-on-year decrease of 227.71% [2]. Shareholder Information - As of September 30, 2025, Shutaishen had 46,500 shareholders, an increase of 46.97% compared to the previous period, with an average of 9,745 circulating shares per person, a decrease of 31.98% [2]. - The company has cumulatively distributed 771 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]. - Among the top ten circulating shareholders, notable changes include a decrease of 3.45 million shares held by the third-largest shareholder, Xingquan Helun Mixed A, and an increase of 3.39 million shares held by the fifth-largest shareholder, Xingquan Heyi Mixed A [3].

Group 1 - The core point of the news is that Shutaishen's stock price dropped by 5.2% to 26.60 CNY per share, with a trading volume of 383 million CNY and a turnover rate of 3.13%, resulting in a total market capitalization of 12.709 billion CNY [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shutaishen includes 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of major fund holdings, one fund under CITIC Prudential has heavily invested in Shutaishen. The CITIC Prudential Zhirui Mixed A Fund (003432) increased its holdings by 60,000 shares in the fourth quarter, bringing the total to 355,000 shares, which accounts for 4% of the fund's net value, making it the sixth-largest holding [2] - The CITIC Prudential Zhirui Mixed A Fund was established on October 21, 2016, with a current size of 134 million CNY. Year-to-date returns are 1.83%, ranking 6888 out of 8861 in its category; the one-year return is 7.03%, ranking 6921 out of 8126; and the return since inception is 72.96% [2] Group 3 - The fund managers of CITIC Prudential Zhirui Mixed A Fund are Wang Rui and Zhu Huiling. Wang Rui has a tenure of 10 years and 276 days, with a total fund asset size of 5.719 billion CNY, achieving a best return of 253.09% and a worst return of -32.84% during his tenure [3] - Zhu Huiling has a tenure of 301 days, managing a total fund asset size of 242 million CNY, with a best return of 7.37% and a worst return of 7.29% during her tenure [3]

Group 1 - The core viewpoint of the news is that Shuyou Shen's stock has shown a significant increase in price recently, with a year-to-date increase of 10.65% and a notable rise of 10.65% over the last five trading days [1] - As of January 9, Shuyou Shen's stock price reached 30.23 yuan per share, with a total market capitalization of 14.443 billion yuan [1] - The company primarily engages in the research, production, and sales of biological products and certain chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] Group 2 - As of September 30, the number of shareholders for Shuyou Shen increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million yuan, a decrease of 227.71% [2] - The company has distributed a total of 771 million yuan in dividends since its A-share listing, but has not paid any dividends in the last three years [3]

Group 1 - The core viewpoint of the news is that Shutaishen's stock has shown significant volatility, with a year-to-date increase of 275.17% and recent fluctuations in trading volume and price [1][2] - As of December 25, Shutaishen's stock price was 27.80 yuan per share, with a total market capitalization of 13.282 billion yuan [1] - The company has experienced a net outflow of main funds amounting to 23.4642 million yuan, with large orders showing a buy-sell imbalance [1] Group 2 - Shutaishen's main business involves the research, production, and sales of biological products and some chemical drugs, with the primary revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] - As of September 30, the company reported a revenue of 181 million yuan for the first nine months of 2025, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.6895 million yuan, a decrease of 227.71% [2] - The company has not distributed any dividends in the last three years, with a total payout of 771 million yuan since its A-share listing [3]

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.01% on December 23, with a current price of 26.88 yuan per share and a total market capitalization of 12.843 billion yuan. The company has seen significant fluctuations in its stock price throughout the year, with a year-to-date increase of 262.75% but a recent decline over the past 20 and 60 days [1]. Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, representing a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.6895 million yuan, a decline of 227.71% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shuyou Shen was 46,500, an increase of 46.97% from the previous period. The average number of circulating shares per shareholder was 9,745, which decreased by 31.98% [2]. Dividend Distribution - Since its A-share listing, Shuyou Shen has distributed a total of 771 million yuan in dividends. However, there have been no dividend distributions in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Xingshan He Run Mixed A ranked as the third-largest shareholder with 12.2691 million shares, a decrease of 3.4519 million shares from the previous period. Xingshan He Yi Mixed A ranked fifth with 9.3396 million shares, an increase of 3.3875 million shares [3].

Group 1 - The core point of the news is that Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. experienced a stock price increase of 5.14%, reaching 32.30 CNY per share, with a trading volume of 505 million CNY and a turnover rate of 3.52%, resulting in a total market capitalization of 15.432 billion CNY [1] - The company was established on August 16, 2002, and went public on April 15, 2011. Its main business involves the research, production, and sales of biological products and some chemical drugs [1] - The revenue composition of the company includes 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of major fund holdings, one fund under Yinhua Fund has a significant position in Shuyou Shen. The Yinhua Growth Smart Selection Mixed A Fund (024455) held 430,300 shares in the third quarter, accounting for 3.48% of the fund's net value, making it the ninth largest holding [2] - The estimated floating profit from this position today is approximately 679,900 CNY [2] - The Yinhua Growth Smart Selection Mixed A Fund (024455) was established on June 20, 2025, with a current size of 253 million CNY and a cumulative return of 5.31% since inception [3]

Group 1 - The core point of the news is that Shutaishen's stock has experienced a significant decline, dropping 5.17% to 30.27 CNY per share, with a total market capitalization of 14.462 billion CNY and a cumulative drop of 18.78% over the last five days [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. specializes in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] Group 2 - From the perspective of major fund holdings, the Dongfang Alpha Fund has increased its stake in Shutaishen, holding 239,500 shares, which represents 6.08% of the fund's net value, ranking it as the eighth largest holding [2] - The Dongfang Alpha Health Industry Mixed Fund A (024357) has incurred a floating loss of approximately 395,100 CNY today and a total floating loss of 1.7672 million CNY during the five-day decline [2] - The fund manager, Meng Yu, has been in charge for 1 year and 362 days, with the fund's total asset size at 306 million CNY and a best return of 18.32% during the tenure [2]

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

Core Viewpoint - The stock of Shuyou Shen has shown significant volatility, with a year-to-date increase of 426.05%, but recent performance indicates a mixed trend with a decline over the past 60 days [2]. Group 1: Stock Performance - As of November 14, Shuyou Shen's stock price rose by 2.04% to 38.98 CNY per share, with a trading volume of 9.15 billion CNY and a market capitalization of 186.24 billion CNY [1]. - The stock has experienced a 14.71% increase over the last five trading days, but a 2.31% decrease over the last 20 days and a 23.54% decline over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decrease of 227.71% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 771 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Xingquan Helun Mixed A and an increase by Xingquan Heyi Mixed A [3].